Cisplatin is used to treat a variety of
tumors, but dose limiting toxicities or intrinsic and acquired resistance limit its application in many types of
cancer including prostate. We report a unique strategy to deliver
cisplatin to
prostate cancer cells by constructing Pt(IV)-encapsulated prostate-specific membrane
antigen (PSMA) targeted nanoparticles (NPs) of
poly(D,L-lactic-co-glycolic acid) (PLGA)-poly(
ethylene glycol) (PEG)-functionalized controlled release
polymers. By using
PLGA-b-PEG nanoparticles with PSMA targeting aptamers (
Apt) on the surface as a vehicle for the
platinum(IV) compound c,t,c-[Pt(NH(3))(2)(O(2)CCH(2)CH(2)CH(2)CH(2)CH(3))(2)Cl(2)] (1), a lethal dose of
cisplatin was delivered specifically to
prostate cancer cells. PSMA aptamer targeted delivery of Pt(IV) cargos to PSMA(+) LNCaP
prostate cancer cells by endocytosis of the nanoparticle vehicles was demonstrated using fluorescence microscopy by colocalization of green fluorescent labeled
cholesterol-encapsulated NPs and early endosome marker EEA-1. The choice of linear hexyl chains in 1 was the result of a systematic study to optimize encapsulation and controlled release from the
polymer without compromising either feature. Release of
cisplatin from the polymeric nanoparticles after reduction of 1 and formation of
cisplatin 1,2-intrastrand
d(GpG) cross-links on nuclear
DNA was confirmed by using a
monoclonal antibody for the adduct. A comparison between the cytotoxic activities of Pt(IV)-encapsulated
PLGA-b-PEG NPs with the PSMA aptamer on the surface (Pt-NP-
Apt),
cisplatin, and the nontargeted Pt(IV)-encapsulated NPs (Pt-NP) against human prostate PSMA-overexpressing LNCaP and PSMA(-) PC3
cancer cells revealed significant differences. The effectiveness of PSMA targeted Pt-NP-
Apt nanoparticles against the PSMA(+) LNCaP cells is approximately an order of magnitude greater than that of free
cisplatin.